financetom
Business
financetom
/
Business
/
Olympics-Taekwondo-Italy's Dell Aquila bows to first-time Olympian in semi-finals
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Olympics-Taekwondo-Italy's Dell Aquila bows to first-time Olympian in semi-finals
Aug 7, 2024 9:54 AM

PARIS, Aug 7 (Reuters) - Italy's taekwondo champion Vito Dell Aquila bowed to Azerbaijan's first-time Olympian Gashim Magomedov in the semi-finals of the men's flyweight in Paris on Wednesday, as he said an injury sapped his performance.

Lesser-known Magomedov, who ranked fifth in flyweight in the world championships of 2022 and 2019, easily beat Olympic gold medallist Dell Aquila 9-4 11-1, capping the second round with a string of kicks to the body.

Magomedov is the only athlete representing his country in taekwondo at the 2024 Olympics.

"I want to say alhamdulillah (praise to god), dreams come true," Magomedov told Reuters after the match.

"I'm in (the) finals," added Russia-born Magomedov, 24, speaking in English. "Many years I think about this, but I don't know. I'm speechless, brother. I'm speechless. I can't understand, brother. I go in final. Subhanallah (glory to Allah)"

Dell Aquila, who won gold in Tokyo, was one of Italy's best hopes for a medal in taekwondo in Paris. He told reporters after the match that he suffered from an injury of the left adductor that prevented him to chase a fast-moving Magomedov.

Dell Aquila had, however, managed to beat athletes from Kazakhstan and Hungary in his two previous bouts.

"I was very prepared, I was in top physical shape, because I was training a lot... but I fought like a broken man," Dell Aquila told reporters after the match.

"I got by in the first two matches, because I hadn't hurt myself too much," he said. "But he (Magomedov) was tough because... you had to chase him with your leg and I can't do that at the moment."

Magomedov is set to fight South Korea's Park Taejoon in the final later on Wednesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved